Five-Year Data in Support of VisionCare's Telescope Implant Technology Featured at Upcoming American Society of Retina Specialist 33rd Annual Meeting

David S. Boyer, MD to Present Data Highlighting the Long Term Effectiveness and Safety of the Telescope Implant for Macular Degeneration

Jul 08, 2015, 09:00 ET from VisionCare Ophthalmic Technologies, Inc.

SARATOGA, Calif., July 8, 2015 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc. ("VisionCare"), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), announced today the scientific presentation on its 60-month data in support of the telescope implant at the upcoming American Society of Retina Specialist (ASRS) 33rd Annual Meeting in Vienna. David S. Boyer, M.D., vitreoretinal specialist at Retina-Vitreous Associates Medical Group in Beverly Hills, CA, will offer the first presentation of the meeting to highlight data from the recently published study "Long-Term (60-month) Results for the Implantable Miniature Telescope: Efficacy and Safety Outcomes Stratified by Age in Patients with End-Stage Age-Related Macular Degeneration" in Clinical Ophthalmology.

The podium presentation is scheduled as follows:

American Society of Retina Specialist 33rd Annual Meeting
July 11-14, 2015, Austria Center Vienna

Saturday, July 11
Session: AMD Neovascular 1
Topic:Long-Term (60-month) Results of the Implantable Miniature Telescope
Time: 8:05-8:13am CET (Central European Time)
Presenter: David S. Boyer, MD
Location:  Austria Center Vienna, Hall A, Level 2

Visit the VisionCare booth (#6) in Vienna to learn more.

About CentraSight and the Telescope Implant
The telescope implant is the integral component of VisionCare's comprehensive treatment program called CentraSight®, which helps patients follow the steps necessary for proper diagnosis, surgical evaluation, implantation and postoperative care.

The Implantable Miniature Telescope (by Dr. Isaac Lipshitz) is indicated for monocular implantation to improve vision in patients greater than or equal to 65 years of age with stable severe to profound vision impairment (best-corrected distance visual acuity 20/160 to 20/800) caused by bilateral central scotomas (blind areas) associated with end-stage AMD. This level of visual impairment constitutes statutory (legal) blindness. Smaller than a pea, the telescope is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation.

The telescope implant is not a cure for End-stage AMD. As with any medical intervention, potential risks and complications exist with the telescope implant. Possible side effects include decreased vision or vision impairing corneal swelling. The risks and benefits associated with the telescope implant are discussed at www.CentraSight.com.

Patients and physicians can learn more about the telescope implant by visiting www.CentraSight.com or calling 1-877-99-SIGHT.

About VisionCare Ophthalmic Technologies
VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA, is a privately-held company. The Company is focused on the development, manufacturing, and marketing of implantable ophthalmic devices and technologies that are intended to improve vision and quality of life for individuals with end-stage age-related macular degeneration. Information on VisionCare can be found at www.visioncareinc.net.

SOURCE VisionCare Ophthalmic Technologies, Inc.



RELATED LINKS

http://www.visioncareinc.net